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EDITORIAL REVIEW
Membrane protein damage and methylation reactions in chronic
renal failure
Natural proteins are prone, once they are synthesized in the
endoplasmic reticulum, to spontaneous, non-enzymatic, molecu-
lar damage. This is represented by examples such as oxidation,
glycosylation, racemization, isomerization and deamidation reac-
tions, which affect a variety of different amino acid residues. Rates
of these non-enzymatic reactions depend on the intrinsic struc-
tural stability of protein molecules, as well as on the cellular and
extracellular micro-environment.
It has been proposed that these modifications in their entirety
should be referred to as "protein fatigue," and the proteins
subject to such posttranslational alterations, as "fatigue damaged
proteins" [1]. The terms are taken from the terminology used in
the field of aerospace engineering.
Structural modifications thus determined can significantly alter
the physical-chemical properties of a protein and therefore impair
its function. These changes, even if minor, involving for example
just one residue over hundreds, are nevertheless able to trigger a
significant modification of function. Damage accumulation can be
dramatic in the case of long lived proteins, particularly in cells and
tissues where protein synthesis is permanently inactivated (such as
the erythrocyte) so that damaged proteins cannot be replaced by
newly synthesized and functionally intact macromolecules.
Among the different protein fatigue damages, attention has
been recently focused on the spontaneous alterations involving
asparaginyl and aspartyl residues. Spontaneous deamidation of
asparaginyl residues, and, less frequently, isomerization of aspar-
tyl residues, can generate atypical L-isoaspartyl residues. The
mechanism of these reactions has been clarified, and it involves
the formation of a common succinimidyl intermediate, followed
by the opening of the ring, yielding, in at least 70% of cases, an
abnormal L-isoaspartyl residue, which is linked to the next residue
through a /3-isopeptide bond, instead of the normal a-peptide
bond [1, 2]. Deamidation is capable of inducing major alterations
of the three-dimensional organization of a protein molecule [1, 2].
For example, alterations associated with the formation of an
L-isoaspartyl residue, such as the presence of an additional
methylcne group in the protein backbone or the negative charge
on the free cx-carboxyl group, can be expected to affect the local
stability of an a helix where present. As a matter of fact the
alterations induced by deamidation on protein structure and
function have been extensively investigated using calmodulin as a
model protein [3—6]. In addition, several other proteins have been
reported to undergo asparaginyl deamidation and/or aspartyl
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isomerization including human epidermal growth factor, human
growth hormone releasing hormone, calmodulin, lysozyme [1, 2].
Relevant to the mechanisms so far discussed is the spontaneous
formation of D-aspartyl residues in proteins. It is acknowledged
that a subset of these racemized residues can in fact be generated,
particularly in long-lived proteins, through the slow racemization
of the succinimide intermediate. D-aspartyl residues have been
found to occur in the /3-amyloid core protein of Alzheimer's
disease. In this condition it has been shown that the presence of
such residues can significantly affect the solubility of this protein
and its deposition in cerebral tissues [7—I
Enzymatic repair of damaged proteins
Normal cells possess the enzymatic machinery to counteract
some of the structural and functional effects of spontaneous
protein damage. It is obvious that the energy expenditure of
synthesizing a protein ex novo is much higher than the one
required to simply modify single residues of a protein. One of such
examples is represented by the protein L-isoaspartate-(D-aspar-
tate) 0 methyltransferase (PCMT type II; type II MTase; EC
2.1.1.77), which selectively catalyzes the S-adenosylmethionine
(AdoMet)-dependent methyl esterification of protein and peptide
free carboxyl groups at the level of altered L-isoaspartyl (and
D-aspartyl) residues [1, 2].
Since 1886 when Willhelm His, the scientist who located the
heart's bundle named after him, described the first known methyl
transfer reaction, leading from pyridine to methylpyridine, more
than 100 methyltransferases have been also discovered, with
hundreds of genes that should encode for the relevant enzymatic
proteins. AdoMet-dependent methyltransferases are by far the
most numerous group of these enzymes, so that this sulfonium
compound is considered the universal methyl donor, which is
probably second only to ATP as regards to the great number of
reactions in which it serves as a substrate. The enzymes known to
date deliver a number of different services in the various living
organisms where they have been found, ranging from the biosyn-
thesis of natural compounds and drug metabolism, to regulatory
functions and housekeeping purposes (Table 1).
Several classes of AdoMet-dependent protein methyltrans-
ferases have been so far identified, including, among others, four
different classes of enzymes, just to mention only those which
transfer a methyl group to specific free carboxyl groups of protein
and peptide substrates [1, 2]. In particular, relevant to the issue of
protein repair is the function of PCMT type II, a ubiquitous
enzyme that has been recently identified to be involved in the
repair of protein and peptide damages induced by the above
mentioned spontaneous deamidation of asparaginyl or isomeriza-
tion of normal aspartyl residues [1, 2, 10]. Brain and blood are, in
mammals, the tissues endowed with the highest enzyme activity
[2]. The enzyme is essentially cytosolic in human red cells, while a
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Two major groups of enzymes can be distinguished, based on the nature
of the methyl accepting substrate. Different major classes of protein
methyltransferases have been characterized based on the atom to which
the methyl group is transferred. Protein 0-methyl transferases () include
four different subclasses of enzymes, which differ for both the nature of the
methylesterified amino acid residue and the biological function of the
reaction. PCMT type II recognizes and modifies altered aspartyl residues
and this reaction initiates the repair of an abnormal isoaspartyl residue.
membrane bound form has also been identified in rat tissues
including brain and kidney cortex [111. The human erythrocyte
enzyme has been purified to homogeneity from human red blood
cells (RBCs) [2, 121. It acts as a monomer with a molecular weight
of 25 kDa, whose sequence is highly conserved when compared to
the homologous enzyme from other mammalian species [2, 121.
Two major isoenzymes with different isoelectric points have been
isolated in different cells types including human erythrocytes. In
humans their sequences show very little variation, particularly in
the C-terminal region, which account for the observed physical-
chemical differences [13, 141. A minor isoform with an interme-
diate isoelectric point between the two major isoenzymes has also
been identified in human erythrocytes [10]. The red cell isoen-
zymes of PCMT type 1! display an identical substrate specificity
when assayed in vitro using purified peptide substrates [2, 151. In
the intact erythrocytes, major substrates for this repair enzyme are
membrane proteins [1, 2].
Evidence for a role in the repair of isopeptide bonds present at
L-isoaspartyl sites, has been obtained by independent research
groups [16—20]. The repair mechanism is partly enzymatic, includ-
ing the methyl esterification step, and partly spontaneous, includ-
ing the non-enzymatic hydrolysis of the methyl ester via suecin-
imide, leading to the conversion of the L-isoaspartyl into a normal
L-aspartyl residue (Fig. 1). As a demonstration of the effective-
ness of this repair on protein function, is the elegant example
provided by Aswad's group with the calcium-binding protein
calmodulin [3, 21]. If deamidated in vitro the protein loses most of
its biological activity, which is in turn quantitatively restored after
this protein is enzymatically methyl esterifled. Evidence of the
effectiveness of this repair function have been provided by inde-
pendent research groups [16, 17, 20], who have also clarified the
mechanism, as it has been depicted above.
Substrates and products of the PCMT type II catalyzed
reaction
As well as other cell types, RBCs are able to synthesize the
methyl donor AdoMet from ATP and exogenously administered
methionine, which is not incorporated into proteins, since protein
synthesis is virtually absent in mature erythrocytes [22]. This
feature has been extensively utilized for selectively identi'ing in
vivo methyl esterified proteins through SDS/PAGE. These mainly
include band 3 integral protein, as well as band 2.1 (ankyrin) and
4.1 cytoskeletal components, and calmodulin [4, 23—25]. As a
matter of fact, RBCs are an excellent model system to study the
reaction catalyzed by the type II PCMT, which virtually represents
the only AdoMet-dependent reaction active in these cells.
S-adenosylhomoeysteine (AdoHcy), the demethylated product
of AdoMet, is the natural, competitive inhibitor of this reaction, as
well as of all AdoMet-dependent enzymatic methylations [26—311.
All AdoMet-dependent methyltransferases are regulated in vivo
by the [AdoMet/[AdoHcy] ratio. This ratio is therefore consid-
ered to be a very sensitive indicator of the presence and the
degree of a potential inhibition not only of this reaction, hut also
of all AdoMet-depent transmethylations. AdoHcy concentration
is normally kept low, intracellularly, by its reversible enzymatic
hydrolysis, catalyzed by AdoHcy hydrolase, to adenosine and
homocysteine (Hey). Thermodynamics actually favor the biosyn-
thetic reaction over hydrolysis, but what happens in vivo is the
effective splitting of AdoHcy to adenosine and Hey, because these
products are rapidly metabolized (Fig. 2). Adenosine (Ado)
enters the purine nucleotide pool [26—311.
The metabolic fate of ilcy
Hey can be metabolized intracellularly through several ways
(Fig. 3): (i) to cystathionine by a reaction catalyzed by cystathi-
onine f3-synthase (C/3S), a vitamin B6-dependent enzyme, which
utilizes serine as the other substrate. CPS is positively modulated
by AdoMet. This is the transsulfuration pathway that leads to the
formation of cysteine as the final product through the action of a
second enzyme, cystathionase [32, 33]; (ii) alternatively, Hey can
be remethylated to methionine through the action of methionine
synthase, a methyleobalamin-dependent enzyme. This step also
requires methyltetrahydrofolate (methylTHF) formed by the en-
zyme methyleneTHF reductase (MTHFR), which is negatively
modulated by AdoMet [32, 33]. An impairment of either meta-
bolic pathways, due to a deficiency of CI3S, or of MTHFR (or
methionine synthase), respectively, but also to a relative or
absolute deficit of their relevant cofactors, can he responsible for
a defective metabolism of Hey. In this respect it has been recently
proposed that hyperhomocysteinemia may also be the result of a
disturbance of the AdoMet-dependent coordinate regulation of
remethylation and transsulfuration of homocysteine, leading to
the interesting hypothesis that any disruption of either pathway
will result in a general impairment of Hey metabolism [33]. (iii)
Hey deamination was found to be negligible in humans [331.
Conversely, it has been recently shown that Hey can be converted
to Hey thiolactone in mammalian cells, as the result of an error
editing activity of methionyl tRNA synthetase, in order to prevent
Hey misincorporation within proteins [34]. Hey thiolactone, is a
highly reactive, toxic metabolite, which can also be reconverted
into Hey by the action of esterases of cells and plasma. Its complex
metabolism is beyond the scope of this article, however, for an
exhaustive review of this topic we refer the reader to McCully
[35—37],
Intracellularly produced Hey can also enter the plasma at this
point, or it can be metabolized elsewhere as in the kidney, or
excreted in the urine, As far as the erythrocyte is concerned, we
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Fig. 1. Mechanism of PCMT type 11-dependent repair of isopeptide bonds in proteins and peptides. The first reaction of this mechanism is the enzymatic
methyl esterification of the free a-carboxyl group of isoaspartyl residue, yielding the isoaspartyl methyl ester of the peptide (step 1; grey-dotted
background). The following steps occur spontaneously: the hydrolysis of the methyl ester through the formation of the succinimide derivative of the
peptide (step 2). The hydrolysis methyl ester, on either side of the nitrogen atom, yields the "repaired" peptide, containing a normal aspartyl residue
(step 4; normal peptide within a black frame), or again the isoaspartyl residue (step 3). Theyield of the repair process at each methylation/demethylation
cycle is about 30%, depending on the nature of the peptide substrate. However, a quantitative conversion of the isoaspartyl peptide into the normal
peptide can be obtained through repeated cycles of the whole pathway.
Fig. 2. AdoHcy enzymatic hydrolysis. Schematic
representation of the reversible hydrolysis of
AdoHcy catalyzed by AdoHcy hydrolase,
yielding adenosine and homocysteine. The
biosynthetic reaction is thermodynamically
favored, while in vivo AdoHcy hydrolysis is
insured due to the rapid removal of its
products. Intracellular accumulation of AdoHcy
can be expected under conditions of defective
removal of its products due, for example, to
Out In hyperhomocysteinemia.
may expect this to be by far the most important mechanism for
eliminating intracellularly produced Hey. in fact, Hey has been
shown to leak out from RBCs in blood samples stored in vitro [38],
and since the RBC membrane is permeable to an inward flux of
Hey as well [281, it has been established that the intracellular
concentration of its derivative, AdoHcy, is also dependent on the
concentration of Hey in the extracellular medium [28]. Therefore,
the level of enzymatic methylation of membrane proteins may be
also considered as a fine indicator of a general derangement of
Hey metabolism, in the presence of significant and chronic
elevations of homocysteinemia.
The ways by which Hey is removed from the body are raising
much interest because of a recent observation that hyperhomo-
cysteinemia is an independent risk factor of vascular disease, that
is, acute coronary ischemia, stroke, as well as peripheral artery,
but also venous thrombosis [39—431. The relationship between
high homocysteine and vascular disease is as strong as the one
between smoking or high blood pressure [40]. Recent studies have
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Fig. 3. General pathways of homocysteine
metabolism. The main ways for the intracellular
formation and metabolism of homocysteine
have been depicted. The intracellular space is
indicated by a light-grey colored rectangle. The
erythrocyte has limited metabolic capabilities
(highlighted by a white area).
shown that Hey induces a proliferation of vascular smooth muscle
cells, the most prominent hallmark of atherosclerosis [44], besides
promoting several other alterations of factors related to the
pathogenesis of atherosclerosis, such as lipoprotein(a), oxygen
radicals, etc. [45—49]. It has been postulated that several thou-
sands of cardiovascular deaths can be prevented by lowering
plasma homocysteine, either by identifying hyperhomocysteine-
mic subjects and treating them with folic acid and its active
compounds, or by supplementing breads, cereals, and other
dietary components with folic acid in low dosages [501.
High levels of Hey have been found in the plasma of chronic
renal failure (CRF) subjects: while normal levels range between 6
and 12 .LM, end-stage renal disease subjects have values between
25 and 40 rM [51—54], a very high range indeed, considering that
high risk cardiovascular subjects are those with more than 15 to 16
/kM [40—42]. In CRF, cardiovascular disease is among the most
common cause of death, accounting for more than one third in
international registries [55], the role of hyperhomocysteinemia as
an independent risk factor for vascular disease has also been
recently assessed in hemodialysis patients [56].
The high levels of Hey found in uremia can be related to (1)
reduced urinary excretion. However, recent results that Guttorm-
sen et al presented at the International Conference on Homocys-
teine Metabolism [57], show that urinary excretion can be actually
increased in CRF patients, and that the urinary excretion of
homocysteine as such is trivial, accounting for only 0.2% of daily
homocysteine production from the body. (2) Also, there can be a
decreased tubular metabolism of homocysteine, but this too is
considered to be a minor determinant, since the GFR correlates
with plasma Hey but not with urinary a2 microglobulin (a marker
of tubular damage) in CRF, and Hey clearance is reduced much
less than creatinine clearance in CRF. Much more important
seems to be (3) a decreased renal metabolism, as shown by
Bostom et al, who demonstrated that homocysteine concentration
is lower in the renal vein than in the renal artery, in the face of a
very low urinary excretion [58, 59].
It is also possible that (4) remethylation to methionine may be
impaired, either in the kidney or elsewhere, due to a relative
deficiency of folic acid or its active derivatives, or to (5) decreased
transsulfuration to cystathionine, due to a deficiency of serine. It
is well known that low plasma levels of serine are present in
uremia [60], but of course this could be instead the consequence
of an increased transsulfuration pathway activity.
Protein methylation in CRF
CRF is characterized by several alterations of the erythrocyte
membrane, expressed by hemolysis, reduced deformability and
increased osmotic fragility, and of the activity of various mem-
brane proteins, such as the erythrocyte Cl/HC03 anion ex-
changer, by a reduced erythrocyte Na/K pump activity, and by
a defect in the activity of the Na/K/2Cl cotransport [61-68].
The end result is certainly a state of deranged cell membrane
function.
Recent results obtained by us show that in CRF patients
compared to control healthy individuals, a significant reduction of
membrane protein methyl esterification is detectable that is due to
a significant increase of the natural inhibitor AdoHcy intracellular
concentration [69]. The patient population was divided into two
groups, one treated conservatively on a low protein dietary
regimen, and with a creatinine clearance ranging between 10 and
40 mI/mm, and one on standard hemodialysis therapy.
In particular, a significant reduction in total membrane protein
methyl esterification was observed either by normalizing the data
for mg of proteins (Fig. 4A), or by cell number (Fig. 4B).
Moreover, the reduction was present in both groups, but was more






Fig. 4. Enzymatic methylation of membrane proteins in intact e,ythrocytes
from CRF patients. Erythrocytes have been freshly prepared from CRF
patients (both under conservative treatment or under hemodialysis) and
from matched normal controls. Methyl esterification has been carried out
by incubating these cells for one hour at 37°C in the presence of methyl
labeled methionine, as the AdoMet in viva precursor. At the end of the
incubation cells have been washed and membranes prepared after hemo-
lysis in hypotonic medium. Methylation of membrane proteins has been
evaluated by liquid scintillation counting. Results are expressed as cpm/
million cells (A) or cpm/mg protein (B). Symbols are: (U) control, N = 24;
() non-dialysis, N = 12; () dialysis, N = 12; * < 0.01. Further details
are in [69].
pronounced in the patients with end-stage kidney failure. Char-
acterization of proteins through SDS/PAGE showed that the
decrease was strikingly evident for cytoskeletal component
ankyriri, band 2.1 [69], which is known to be involved in the
maintenance of membrane stability and integrity [25]. A reduction
was present also for the other methyl accepting substrates, that is
band 3 (AE-1 protein), band 4.1 and 4.2, but did not reach
statistical significance.
In addition, HPLC analysis of the same RBC samples subject to
methylation evidenced a several-fold rise in AdoHcy intracellular
levels, while AdoMet concentration was not different from con-
trols, resulting in a lower [AdoMet]/[AdoHcy] ratio in both the
patient groups (Fig. 5). The specific activity of the enzyme PCMT
type II was not different from controls [69], indicating that this
enzyme is malfunctioning not because of some intrinsic damage to
its structure or to altered protein content, but because it is
0
Fig. 5. Intracellular AdoMetiAdoffcy concentration ratio, in eythrocytes
from CRF patients. AdoMet and AdoHey intracellular concentrations have
been measured in erythrocytes from CRF patients (both under conserva-
tive treatment or under hemodialysis). The two compounds have been
simultaneously determined using HPLC. The results are expressed as
[AdoMet]/[AdoHcy] in both patient groups compared to normal controls.
Since Adoflcy is a competitive inhibitor of AdoMet-dependent enzymes
and because of the close values of the Km for AdoMet and Ki for AdoHcy,
lower values of this ratio indicate the existence of an intracellular
environment less suitable for correct methylation. Symbols are: (U)
controls; () non-dialysis; () dialysis; *P < 0.001. Further details are in
[69]. Reproduced with permission from J Clin Invest 91:2497—2503, 1993
(The American Society for Clinical Investigation).
inhibited by a powerful compound, AdoHey. Cytosolic GOT
activity, a marker of cell age [70], did not correlate with either
methylation levels or with AdoHcy or AdoMet concentrations,
demonstrating that these parameters were not influenced by cell
age.
The data, taken as a whole, are consistent with the notion that
in CRF structural damages accumulate in erythrocyte membrane
proteins and are not adequately repaired.
Role of Hey in the increase of intracellular AdoHcy
In the effort to investigate the origin of AdoHcy increase, we
measured plasma and RBC Hey levels, AdoHcy, AdoMet, and
Ado intracellular levels, and AdoHcy hydrolase specific activity. A
hemodialysis patient group was compared to normal healthy
controls, Plasma and red cell Hey were significantly higher in the
patient group compared to control subjects, and were both
positively and significantly correlated to AdoHey intracellular
levels. Ado and AdoMet levels, and AdoHey hydrolase specific
activity were not significantly different between the two groups
[71]. In addition, we identified positive correlation between
homocysteinemia and the intracellular concentration of AdoHcy
in CRF patients (Fig. 6) [71].
To further substantiate the role that increased Hey plays in the
elevation of AdoHcy, we designed a series of in vitro experiments.
Erythrocytes from control and dialysis patients were incubated
with or without 50 LM Hey (a concentration comparable to plasma
levels actually found in vivo in these patients), and tracing Ado.
The enzymatic formation of labeled AdoHcy from Hey at that
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Fig. 6. Correlation between hornocysteinemia and intracellular AdoHcy
concentration in CRF patients. Total plasma Hcy concentration was
determined by HPLC. The intracellular concentration of AdoHcy was also
determined, by HPLC, in erythrocyte samples from the same patients. Full
symbols: CRF patients; open symbols: controls. A positive simple corre-
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Fig. 8. Reduction of intracellular AdoHcy concentration as a result of Hey
removal. Erythrocytes isolated from CRF patients where incubated in the
presence or in the absence of 50 jM Hey. At the indicated time points
aliquots were withdrawn and intracellular AdoHcy concentration was
evaluated by HPLC. AdoHcy concentration in the cells incubated without
Hey is expressed as percentage of the values obtained in parallel samples
incubated with Hey. (From Perna AF ct al [71], reprinted with
permission).
Therefore, we were able to conclude that removing Hey from the
incubation medium leads to the gradual disappearance of the
elevated levels of AdoHcy, which are in fact of a reversible nature
(Fig. 8).
The results allowed us to conclude that plasma and red cell Hey
levels actually found in uremia can be effectively responsible for
the intracellular accumulation of the toxic compound AdoHcy.
Conclusions and future perspectives
The overall importance of our work taken as a whole lies, in our
opinion, in the fact that (1) a pathophysiological link between
AdoHcy, a potent inhibitor of methyltransferases, and Hey can be
pinpointed in uremia; (2) AdoHey can thus be considered a
prospective highly toxic metabolite of Hey, since it is able to
interfere with many AdoMet-dependent pathways involved in the
regulation of crucial cell functions; and (3) furthermore, these
variations can be subject to pharmacological treatment, with
compounds such as folic acid and its active derivatives.
Regarding the first point, the demonstration that the levels of
Hey actually found in uremia not only can influence the uremic
patient risk of cardiovascular disease, but also can determine an
increase in the intracellular levels of a known inhibitory com-
pound, is in our opinion of major importance. Most experimental
evidence on the effects of Hey on various cellular parameters are
designed to assess its role in diseases such as genetic homocystin-
uria, because it represented the first model where the relationship
between Hey and premature atherosclerosis was observed. But in
this disease Hey levels are in the high micromolar range [47—49].
On the contrary, we showed that even a modest increase, such as
it is present in uremic patients, can determine tangible effects that
Fig. 7. AdoHcy formation in isolated etythrocytes from CRF patients.
Erythrocytes isolated from both CRF patients and normal subjects where
incubated in the presence (R) or in the absence () of 50 M Hey and
trace amounts of radioactive Ado. After 5' cytosol was rapidly prepared
and AdoHey analysis performed by HPLC. Radioactivity associated with
AdoHey peak was measured. (From Perna AF et al [71], reprinted with
permission).
increased, in vitro, in erythrocytes from both control and uremic
patients (Fig. 7) [71].
In another experiment, two different subsets of erythrocytes
from uremic patients were incubated in vitro in the presence and
absence of 50 .tM Hey. A significant reduction of intracellular
AdoHcy was observed in the subset incubated without Hey over
time, compared to the identical samples incubated in presence of
50 .LM Hey, with a half life of approximately 270 minutes.
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Table 2. Cellular functions which may be affected by AdoHcy in
uremia
Process/reaction Reference
Cell growth and carcinogenesis (73—77)
Lymphocyte chemokinetic response (78, 79)
Insulin release from the pancreas (80, 81)
Interferon synthesis (82, 83)
Norepinephrine uptake and release in brain (84—87)
Catecholamine degradation (29, 31)
Conversion of phosphatidylethanolamine (29, 31)
to phosphatidylcholine
Brain histamine content (88, 89)
Serotonin and dopamine turnover (90, 91)
can be quantified in vitro. In addition, uremia represents the first
pathological condition in which a role of AdoHcy as methylation
inhibitor is evidenced. In fact, even if there is a disruption in the
protein methylation pattern in another pathology (such as sphero-
cytosis), it is not due to AdoHcy [23, 72].
The second point stated above is the most intriguing, because it
calls for several speculations. AdoMet-dependent reactions exist
in the transfer of a methyl group, and are catalyzed by several
different enzymes to a variety of acceptors, such as proteins,
nucleic acids, phospholipids, neurotransmitters like norepineph-
rifle, and other small molecules, with different biological func-
tions. AdoHcy affects these enzymes in a fashion that depends on
the Ki values for AdoHcy and Km values for AdoMet [29].
Therefore, if it is proven that AdoHcy also increases in cell types
other than erythrocytes in response to the Hcy elevation in blood,
it will be likely that a similar inhibitory action would be exerted on
other cellular functions modulated by AdoMet-dependent en-
zymes (Table 2).
Regarding the third point, several studies have shown that Hcy
plasma levels can be lowered in uremia by treatment with folic
acid, a compound that favors remethylation of Hey to methionine
[92—94]. Hemodialysis can only partially lower plasma Hcy [52],
while folates abate its levels in an even fashion. Folate levels are
not low in uremia either in plasma or in RBCs, but a relative
deficit has been hypothesized [92]. Finally, our in vitro experi.
ments indicate that if Hey levels are lowered, AdoHcy concentra-
tion can be lowered as well.
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